afatinib(redirected from Gilotrif)
afatinib(a-fa-ti-nib ) ,
Pregnancy Category: D
Pharmacologic: kinase inhibitors
Pharmacologic: kinase inhibitors
First-line treatment of metastatic non-small cell lung cancer (NSCLC) where the tumor has a specific epidermal growth factor receptor (EGFR) deletion or substitution mutation detectable by an FDA-approved test.
Inhibits tyrosine kinases which results in slowed proliferation of specific tumor cell lines
Decreased spread of NSCLC
Absorption: Well abosrbed (92%) following oral administration; absorption is decreased by high fat meal.
Metabolism and Excretion: Metabolites occur partly as protein-bound products. Excretion is primarily fecal (85%) as parent drug; 4% excreted in urine.
Half-life: 37 hr
Time/action profile (improved progression-free survival)
|PO||3 mos||12 mos||20 mos|
Contraindicated in: Lactation: Discontinue drug or discontinue breast feeding; Obstetric: May cause fetal harm.
Use Cautiously in: Moderate-severe renal or hepatic impairment (dose adjustment may be necessary);genetic implication Asian ethnicity (may be ↑ susceptible to interstitial lung disease); Obstetric: Patients with child-bearing potential (highly effective contraception should be used during and for at least 2 wks after last dose); Pediatric: Safe and effective use in children has not been established.
Adverse Reactions/Side Effects
Ear, Eye, Nose, Throat
- interstitial lung disease (life-threatening)
- hepatic toxicity (life-threatening)
- diarrhea (most frequent)
- ↓ appetite
- cutaneous reactions (including bullous/blistering/exfoliating reactions, acneiform erruptions and palmar-plantar erythrodysesthesia)
- dry skin
Fluid and Electrolyte
Drug-Drug interactionConcurrent use of P-gp inhibitors including amiodarone, cyclosporine, erythromycin, itraconazole, ketoconazole, quinidineritonavir, saquinavir, tacrolimus, or verapamil ↑ blood levels and the risk of toxicity; dosage adjustment may be necessary (ritonavir may be given concurrently or 6 hr after).Concurrent use of P-gp inducers including carbamazepine, phenobarbital, phenytoinrifampicin or rifampin ↓ blood levels and may ↓ effectiveness; dosage adjustment may be necessary.
Oral (Adults) 40 mg/day; concurrent use of P-gp inhibitors—reduce dose by 10 mg/day if necessary; concurrent use of P-gp inducers—increase dose by 10 mg/day if necessary. Dose reductions recommended for various toxicities. Continue until disease progression or occurrence of unacceptable toxicity
Tablets: 20 mg, 30 mg, 40 mg
- Monitor for diarrhea; occurs frequently. Provide patient with an antidiarrheal agent (loperamide) at the onset of diarrhea and until diarrhea ceases for 12 hrs. If diarrhea is severe and lasts more than 48 hr despite use of antidiarrheal agent (Grade 2 or higher), withhold afatinib until diarrhea resolves to Grade 1 or less, then resume with reduced dose of 10 mg/day.
- Assess for cutaneous reactions (bullous, blistering, exfoliative lesions; rash, erythema, acneiform rash) periodically during therapy. Discontinue afatinib if life-threatening lesions or prolonged Grade 2 cutaneous lesions lasting ≥7 days, intolerable Grade 2, or Grade 3 cutaneous reactions occur. Withhold afatinib until reaction resolves to Grade 1 or less and resume at 10 mg/day.
- Monitor for signs and symptoms of interstitial lung disease (lung infiltration, pneumonitis, acute respiratory distress syndrome, allergic alveolitis; genetic implication may occur more commonly in patients of Asian ethnicity. Withhold afatinib if symptoms occur; discontinue if interstitial lung disease is confirmed.
- Lab Test Considerations: Monitor liver function tests periodically during therapy. If severe decline in liver function occurs, discontinue afatinib. May cause ↑ AST and ALT.
- May cause hypokalemia.
Potential Nursing DiagnosesDiarrhea (Side Effects)
- Oral: Administer once daily on an empty stomach, at least 1 hr before or 2 hrs after meals.
- Instruct patient to take afatinib as directed. Take missed dose as soon as remembered unless within 12 hrs of next dose, then omit and take next dose at scheduled time; do not double doses.
- Caution patient to notify health care professional if signs and symptoms of keratitis (acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye) occur. Withhold if symptoms occur; if ulcerative keratitis is confirmed, discontinue afatinib. Advise patient that use of contact lenses is also a risk factor.
- Advise patient to wear sunscreen and protective clothing during therapy to minimize risk of skin disorders.
- Inform patient that diarrhea occurs in most patients and may cause dehydration and renal impairment. Notify health care professional if diarrhea is severe or persistent, if new or worsening lung symptoms (difficulty breathing, shortness of breath, cough, fever), symptoms of liver problems (yellow skin or whites of eyes, dark brown urine, pain on right side of abdomen, unusual bleeding or bruising, lethargy) or if symptoms of left ventricular dysfunction (shortness of breath, exercise intolerance, cough, fatigue, swelling or ankles or feet, palpitations, sudden weight gain) occur.
- Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
- Advise female patients to use highly effective contraception during and for at least 2 wks after last dose and to avoid breast feeding. If pregnancy occurs, instruct patient to notify health care professional immediately.
- Decreased spread of non-small cell lung cancer.
Drug Guide, © 2015 Farlex and Partners